Details

Autor(en) / Beteiligte

• Fineberg, N.A.
• Van Ameringen, M.
• Drummond, L.
• Hollander, E.
• Stein, D.J.
• Geller, D.
• Walitza, S.
• Pallanti, S.
• Pellegrini, L.
• Zohar, J.
• Rodriguez, C.I.
• Menchon, J.M.
• Morgado, P.
• Mpavaenda, D.
• Fontenelle, L.F.
• Feusner, J.D.
• Grassi, G.
• Lochner, C.
• Veltman, D.J.
• Sireau, N.
• Carmi, L.
• Adam, D.
• Nicolini, H.
• Dell'Osso, B.

Titel

How to manage obsessive-compulsive disorder (OCD) under COVID-19: A clinician's guide from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the European College of Neuropsychopharmacology

Ist Teil von

• Comprehensive psychiatry, 2020-07, Vol.100, p.152174-152174, Article 152174

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2020

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• In response to the emerging crisis and growing calls from patients and clinicians for guidance [5], a working group of clinical experts from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network of the European College of Neuropsychopharmacology (OCRN) have produced this consensus statement with the aim of delivering pragmatic guidance at the earliest opportunity to clinicians for managing this complex challenge. Based on the risks associated with exposure and response prevention (ERP) in the pandemic (see below), and uncertainty as to which of the two evidence-based treatments, pharmacotherapy or cognitive behaviour therapy (CBT), represents the most efficacious first line treatment modality [11], pharmacotherapy should be the first option for adults and children with OCD with contamination, washing or cleaning symptoms during the COVID-19 pandemic. Consider A) type of medication; most patients should receive an SSRI, or if not responsive, another SSRI and as a third choice clomipramine (for which an ECG may be required in certain patient groups); Note US Food and Drug Administration "black box" warnings or advice from equivalent national regulatory authorities regarding increased risk in young people and other vulnerable patient groups. Check for adverse effects and be available for any concerns related to "activation" or newly emergent or increased suicidal ideation, which in the young can be mitigated by starting treatment at a low dose and titrating more gradually; B) dosage; if the patient is on a suboptimal dose, consider increasing it, paying attention to any contraindications; C) SSRI-resistance; consider a low dose of adjunctive antipsychotic (aripiprazole, risperidone, quetiapine, olanzapine), especially if a tic is present; D) adherence; ensure the patient is able to obtain an adequate supply and is taking the treatment regularly.